Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Relmada Therapeutics' (NASDAQ:RLMD) lead asset REL-1017 as a monotherapy for the treatment major depressive disorder (MDD). Relmada shares traded in a range of $26.02 to $27.96 on a day volume of 173.79 thousand shares, closed regular trading session at $27.25. The company shares are currently trading down 5 percent at $25.89 in the after-hours session.
ClearPoint Neuro (NASDAQ:CLPT) announced the U.S. Food and Drug Administration (FDA) 510(k) clearance to its Maestro Brain Model, intended for automatic labeling, visualization, volumetric and shape quantification of segmentable brain structures from a...
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧